Cargando…
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Poor medication adherence is a pervasive issue with considerable health and socioeconomic consequences. Although the underlying reasons are generally understood, traditional intervention strategies rooted in patient-centric education and empowerment have proved to be prohibitively complex and/or ine...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041531/ https://www.ncbi.nlm.nih.gov/pubmed/36973491 http://dx.doi.org/10.1038/s41573-023-00670-0 |
_version_ | 1784912740547035136 |
---|---|
author | Baryakova, Tsvetelina H. Pogostin, Brett H. Langer, Robert McHugh, Kevin J. |
author_facet | Baryakova, Tsvetelina H. Pogostin, Brett H. Langer, Robert McHugh, Kevin J. |
author_sort | Baryakova, Tsvetelina H. |
collection | PubMed |
description | Poor medication adherence is a pervasive issue with considerable health and socioeconomic consequences. Although the underlying reasons are generally understood, traditional intervention strategies rooted in patient-centric education and empowerment have proved to be prohibitively complex and/or ineffective. Formulating a pharmaceutical in a drug delivery system (DDS) is a promising alternative that can directly mitigate many common impediments to adherence, including frequent dosing, adverse effects and a delayed onset of action. Existing DDSs have already positively influenced patient acceptability and improved rates of adherence across various disease and intervention types. The next generation of systems have the potential to instate an even more radical paradigm shift by, for example, permitting oral delivery of biomacromolecules, allowing for autonomous dose regulation and enabling several doses to be mimicked with a single administration. Their success, however, is contingent on their ability to address the problems that have made DDSs unsuccessful in the past. |
format | Online Article Text |
id | pubmed-10041531 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-100415312023-03-27 Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems Baryakova, Tsvetelina H. Pogostin, Brett H. Langer, Robert McHugh, Kevin J. Nat Rev Drug Discov Review Article Poor medication adherence is a pervasive issue with considerable health and socioeconomic consequences. Although the underlying reasons are generally understood, traditional intervention strategies rooted in patient-centric education and empowerment have proved to be prohibitively complex and/or ineffective. Formulating a pharmaceutical in a drug delivery system (DDS) is a promising alternative that can directly mitigate many common impediments to adherence, including frequent dosing, adverse effects and a delayed onset of action. Existing DDSs have already positively influenced patient acceptability and improved rates of adherence across various disease and intervention types. The next generation of systems have the potential to instate an even more radical paradigm shift by, for example, permitting oral delivery of biomacromolecules, allowing for autonomous dose regulation and enabling several doses to be mimicked with a single administration. Their success, however, is contingent on their ability to address the problems that have made DDSs unsuccessful in the past. Nature Publishing Group UK 2023-03-27 2023 /pmc/articles/PMC10041531/ /pubmed/36973491 http://dx.doi.org/10.1038/s41573-023-00670-0 Text en © Springer Nature Limited 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Baryakova, Tsvetelina H. Pogostin, Brett H. Langer, Robert McHugh, Kevin J. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems |
title | Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems |
title_full | Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems |
title_fullStr | Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems |
title_full_unstemmed | Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems |
title_short | Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems |
title_sort | overcoming barriers to patient adherence: the case for developing innovative drug delivery systems |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041531/ https://www.ncbi.nlm.nih.gov/pubmed/36973491 http://dx.doi.org/10.1038/s41573-023-00670-0 |
work_keys_str_mv | AT baryakovatsvetelinah overcomingbarrierstopatientadherencethecasefordevelopinginnovativedrugdeliverysystems AT pogostinbretth overcomingbarrierstopatientadherencethecasefordevelopinginnovativedrugdeliverysystems AT langerrobert overcomingbarrierstopatientadherencethecasefordevelopinginnovativedrugdeliverysystems AT mchughkevinj overcomingbarrierstopatientadherencethecasefordevelopinginnovativedrugdeliverysystems |